Breaking News, Collaborations & Alliances

Samsung Biologics Signs $1.24B Manufacturing Deal with Asia-Based Pharma Company

Production will take place at Samsung Biologics’ biomanufacturing site in Songdo, South Korea.

Author Image

By: Charlie Sternberg

Associate Editor

Samsung Biologics, a global contract development and manufacturing organization (CDMO), has inked a $1.24 billion contract manufacturing deal with an Asia-based pharmaceutical company—the largest contract signed by a single client.   Production will take place at Samsung Biologics’ biomanufacturing site in Songdo, South Korea and the contract runs through December 2037. With the latest agreement, the company’s accumulated contract for 2024 surpasses $3.3 billion.   “We are pleased to strateg...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters